Publications

The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines.

Thomas TM. et al, (2023), Human vaccines & immunotherapeutics, 19

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Silk SE. et al, (2023), Med (New York, N.Y.)

Systematic review of the diagnosis and management of necrotising otitis externa: Highlighting the need for high-quality research.

Takata J. et al, (2023), Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 48, 381 - 394

UK consensus definitions for necrotising otitis externa: a Delphi study.

Hodgson SH. et al, (2023), BMJ Open, 13

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.

Odera DO. et al, (2023), Science translational medicine, 15

Characteristics, management and outcome of a large necrotising otitis externa case series: need for standardised case definition

Hodgson SH. et al, (2022), The Journal of Laryngology & Otology, 136, 604 - 610

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Hodgson SH. et al, (2022), Clinical and translational science, 15, 524 - 534

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.

Kimingi HW. et al, (2022), Frontiers in immunology, 13

Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders

Chi PC. et al, (2021), Trials, 22

Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal Testing

Vanderslott S. et al, (2021), Science, Technology, & Human Values, 016224392110570 - 016224392110570

Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom

Vanderslott S. et al, (2021), BMJ Global Health, 6, e006305 - e006305

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Analysis of peripheral blood B and Tfh cells as predictors of antibody responses in individuals receiving candidate blood-stage malaria vaccines in a Phase Ia clinical trial

Elias S. et al, (2014), Malaria Journal, 13

Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations

Hodgson S. et al, (2014), Malaria Journal, 13

Cookies on this website

Publications